NFE2L2 and cancer: Given NRF2’s pivotal role in cancer progression and resistance to various therapies, including chemotherapy, radiotherapy, immunotherapy, and KRAS G12C inhibitors, there is increasing interest in developing PET tracers to visualize NRF2 activation in vivo (176, 177).